Application | Comment | Organism |
---|---|---|
drug development | cardiac 12/15-LOX is involved in the development of heart failure and inhibition of 12/15-LOX may be a novel treatment for this condition | Mus musculus |
Cloned (Comment) | Organism |
---|---|
transgenic mice overexpressing 12/15-LOX in cardiomyocytes | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
heart | - |
Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
12/15 lipoxygenase | - |
Mus musculus |
12/15-LOX | - |
Mus musculus |
Alox15 | - |
Mus musculus |
Organism | Comment | Expression |
---|---|---|
Mus musculus | 12/15-LOX is markedly upregulated in heart failure, cardiac expression is upregulated during pressure overload | up |
General Information | Comment | Organism |
---|---|---|
physiological function | increased expression of 2/15-LOX causes heart failure. 2/15-LOX induces cardiac inflammation. Alox15 transgenic mice develop systolic dysfunction. Cardiac fibrosis increases in Alox15 transgenic mice with advancing age and is associated with the infiltration of macrophages. Cardiac expression of monocyte chemoattractant protein 1 is up-regulated in Alox15 transgenic mice compared with wild-type mice. Disruption of 12/15-LOX significantly reduces cardiac monocyte chemoattractant protein-1 expression and macrophage infiltration, thereby improving systolic dysfunction induced by chronic pressure overload | Mus musculus |